Steven Appleby, MD
Interventional Cardiology · Long Beach, CANPI 1629126644
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,750 of the $59,464 with a category attached, or 82.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 90.6% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $16,139 and has fallen 87.3% since, to $2,044 in 2025.
Across 316 payments — averaging $188.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$54K
- GSK$925
- Biotronik Inc.$805
- Johnson & Johnson$714
- Boehringer Ingelheim$524
- Novartis$453
- plus $2K from 35 others
What the payments were for
- Speaking & faculty fees$48,75082%
- Travel & lodging$2,3034%
- Food & beverage$8,32514%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 90 | $53,901 |
| GSK | 35 | $925 |
| Biotronik Inc. | 17 | $805 |
| Johnson & Johnson | 42 | $714 |
| Boehringer Ingelheim | 25 | $524 |
| Novartis | 22 | $453 |
| Medtronic | 3 | $179 |
| Shockwave Medical, Inc | 1 | $168 |
| Pfizer | 7 | $165 |
| Abbott | 4 | $155 |
| E.r. Squibb & Sons, L.L.C. | 8 | $147 |
| Amgen | 5 | $129 |
| Amarin Pharma, Inc. | 5 | $105 |
| AstraZeneca | 5 | $101 |
| Merck | 4 | $100 |
| AbbVie(2 entities) | 3 | $73 |
| Nestle Healthcare Nutrition Inc. | 3 | $68 |
| Cardiva Medical, Inc. | 3 | $65 |
| Pulmonx Corporation | 3 | $59 |
| Therapeuticsmd, Inc. | 3 | $59 |
| Kestra Medical Technology Services, Inc. | 3 | $51 |
| Abiomed | 1 | $44 |
| Grifols USA, LLC | 2 | $43 |
| Bayer | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Boston Scientific | 1 | $40 |
| Philips North America LLC | 2 | $39 |
| Advanced Respiratory, Inc | 1 | $30 |
| Novo Nordisk | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Biosense Webster, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$52,048
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$168
- Solia$123
- XARELTO$123
- Micra$100
How this compares
$59,464 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 434 | $391,171 |
| XareltoRivaroxaban | 75 | $93,385 |
| Repatha SureclickEvolocumab | 60 | $68,769 |
| EntrestoSacubitril/Valsartan | 36 | $40,485 |
| BrilintaTicagrelor | 22 | $17,386 |
| VascepaIcosapent Ethyl | 16 | $11,275 |
| Rosuvastatin Calcium | 417 | $8,266 |
| Atorvastatin Calcium | 685 | $7,142 |
| Flecainide Acetate | 114 | $5,718 |
| Losartan Potassium | 440 | $5,615 |
| Metoprolol Succinate | 328 | $4,130 |
| Carvedilol ErCarvedilol Phosphate | 13 | $3,962 |
| Amlodipine Besylate | 521 | $3,301 |
| Ezetimibe | 97 | $3,029 |
| Ranolazine ErRanolazine | 20 | $2,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $165 | $391,171434 claims |
| Johnson & JohnsonXarelto | $714 | $93,38575 claims |
| NovartisEntresto | $453 | $40,48536 claims |
| AstraZenecaBrilinta | $101 | $17,38622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Long Beach
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.